Novartis' Gilenya fails in study for a type of MS

ZURICH (Reuters) - Novartis AG said on Monday its drug Gilenya failed to meet its main goal in a late-stage study as a treatment for primary progressive multiple sclerosis (PPMS).
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news